Veran Medical continues its mission to stage shift cancer with the launch of two new navigation software applications and a new navigated catheter designed to help diagnose and guide treatment of small suspicious nodules likely to be early stage lung cancer. Veran debuted the new software and new navigated catheter to physicians attending the annual American Thoracic Society meeting in San Diego, CA earlier this week.

Veran has enhanced its industry leading software, making it even simpler for physicians to use for both the SPiN Planning™ and SPiN Drive® software applications to assist in the early diagnosis and treatment of lung cancer. The new Ultra HD Airway Segmentation provides a superior map and enables physicians to better target even the smallest nodules. In addition, Veran has made a great advancement on physician and hospital support with the introduction of vSupport™ Connect, on-demand secure screen sharing for live physician directed clinical support.

Veran also debuted a new SPiN Access Catheter™, an extended working channel navigated by an Always-On Tip Tracked® guidewire. The SPiN Access Catheter™ provides lung specialists a catheter-based approach they are familiar with, but with the added advantages of a more accurate 3D map for navigation, respiratory gating, and compatibility with Always-On Tip Tracked® sampling instruments. This new catheter enables more accurate 3D navigation without the need for intraprocedural fluoroscopy during sampling.

“The expanding adoption of lung cancer screening has given us a real opportunity to catch cancer earlier and save lives, but only if we can help physicians reach the smallest nodules,”said Veran Medical CEO Jason Pesterfield. “Our SPiN System™ is clinically proven to help physicians reach the smallest nodules, and our new software and SPiN Access Catheter™ provide additional flexibility to help physicians reach and guide treatment for early stage cancer when patients have the best prognosis.”

Veran’s next generation SPiN Thoracic Navigation System™ offers an industry leading precision thoracic guidance platform that allows lung specialists to seamlessly transition between a navigated endobronchial approach and a navigated transthoracic approach utilizing SPiN Perc™, to help physicians rapidly and definitively diagnose lung cancer. A published clinical study utilizing a multi-modality approach, including Veran’s SPiN System™ and SPiN Perc™, have demonstrated a 92% diagnostic yield.

Lung Cancer remains the number one cancer killer worldwide. 94 million current or former smokers remain at elevated risk in the U.S. alone. More than 8 million people in the U.S. currently meet the criteria for lung cancer screening. When suspicious lesions are discovered, patients need answers. But mounting clinical data suggests that a large percentage of the hundreds of thousands of bronchoscopies performed every year on suspected lung cancer patients are non-diagnostic—delaying potential life saving therapy.

 

Join us at #AWSSummitNYC July 17! Register here: https://t.co/Cqu0wS0ExJ

JUST LAUNCHED: The Air Liquide 2018 Scientific Challenge! The scientific community is invited to submit proposals for using Essential Small Molecules to contribute to a more #sustainable world. Learn more: https://t.co/6ghfy6P5zK